GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery and development of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial target sequence and optogenetics technology platforms. Its lead product candidates include GS010, an AAV2 based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by mutation of the ND4 gene; and GS030 that is in Phase I/II trial for the treatment of retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France.